Freenome Recieves $160 Million in Funding

Want to share this story?

South San Francisco based startup Freenome announced it raised new funding to grow its early cancer detection platform.

The startup announced it has raised $160 million in Series B funding from dual lead investors RA Capital Management and Polaris Partners. Other investors include Andreessen Horowitz, Roche Venture Fund, BrightEdge Ventures, Verliy Life Sciences, Data Collective, Google Ventures, Kaiser Permanente Ventures, T. Rowe Price, Section 32 and Perceptive Advisors.

The startup has raised $238 million in funding in over four rounds since 2016.

Freenome is a biotech company that built a multiomics platform for early cancer detection. It combines deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among several biomarkers.

The startup plans to use the new funding to further development of its early cancer detection blood test powered by its platform.